STERIPACK GROUP LIMITED

SHL Medical and SteriPack Group have entered a non-exclusive strategic partnership. The collaboration aims to establish a pre-validated final assembly service at the SteriPack facility in Poland, offering enhanced flexibility in supply chain strategies for their customers. This partnership extends high-quality Contract Manufacturing Organization (CMO) options to Europe, complementing SHL Medical's existing services in the United States. Markus Puusepp, Chief Growth Officer at SHL Medical, expressed excitement about the partnership, highlighting its significance stating "This partnership is a significant addition to the Molly® platform value proposition. We share common values with SteriPack, from a focus on the customer to a commitment to quality, making the decision to collaborate straightforward." Recognizing the importance of flexibility and time-to-market, especially in clinical production, the partnership with SteriPack will provide SHL Medical's customers with highly flexible and personalized final assembly and packaging solutions. This is particularly advantageous for handling small batches in clinical supply and serving niche markets such as rare diseases. SHL Medical aims to deliver tailored solutions through the Molly platform, ensuring improved service, faster timelines, and a streamlined supply chain for its diverse customer base. John Ward, VP Pharmaceutical Solutions at SteriPack Group, expressed the company's eagerness to support SHL Medical and its customers, offering quality and flexible solutions to the fast-moving pharmaceutical market. "SteriPack Group looks forward to supporting SHL Medical and their customers in providing quality and flexible solutions to a fast-moving market. With an emphasis on creating service solutions designed around specific customer requirements, this partnership will make the process of working with the Molly® platform an easy decision," he said. The partnership aims to simplify the process of working with the Molly® platform, providing service solutions tailored to specific customer requirements.

SteriPack, a contract packing organisation serving the pharmaceutical industry, has announced a strategic partnership with SHL Medical, a provider of advanced drug delivery systems. The partnership will establish a pre-validated, highly flexible final assembly and secondary packing service at the SteriPack facility in Poland for SHL’s second-generation Molly 1.0ml autoinjector platform, adding to its small to mid-volume offering in Europe. The collaboration between SteriPack and SHL Medical leverages the strengths of both organisations to provide high-quality final assembly and contract packing options for pharmaceutical companies seeking support with the complex localisation often associated with small to mid-sized volumes of targeted, self-administered drugs. This latest alliance adds to SteriPack’s growing portfolio of global autoinjector platform partners. The partnership is testament to SteriPack’s experience devising highly tailored solutions using its specialist equipment and tooling, and the value the company places on flexibility and time-to-market for project launches. Markus Puusepp, SHL Medical’s chief growth officer, expressed his enthusiasm about the partnership, stating: “This partnership is a significant addition to the Molly platform value proposition. We share common values with SteriPack, from focus on the customer to a commitment to quality, making the decision to collaborate straightforward.” John Ward, SteriPack Group’s VP pharmaceutical solutions said: "SteriPack Group looks forward to supporting SHL Medical and their customers in providing quality and flexible solutions to a fast-moving market. With an emphasis on creating service solutions designed around specific customer requirements, this partnership will make the process of working with the Molly platform an easy decision.”

SteriPack Group has appointed Jason Anderson as chief executive officer with immediate effect. Anderson has held a variety of senior roles with globally recognised and companies such as Saint-Gobain, McKinsey, and BASF. His most recent role was with Enovis (DJO Global) where he held the position of president, Bracing and Supports. David Lennon, chair of SteriPack commented: “We are very pleased to have Jason join us to lead the company in what we believe will be the most dynamic period of growth in our history. His experience in building global businesses will be invaluable to us as we continue our journey as one of the fastest growing CDMO’s in the market today. In addition, the company has announced the appointment of Bobby O’Connor to the new role of chief commercial officer. Reporting directly to the CEO, O’Connor has over two decades of experience leading international commercial teams selling into the global pharmaceutical, medtech and healthcare markets worldwide and most recently held the position of SVP – Healthcare with Westrock, a specialist in the pharma & healthcare secondary packaging market.